Dose-escalation Study of Single Dose GHB04L1 in Healthy Adults

Inclusion Criteria: * Healthy male volunteers, 18-50 years * Seronegative for H5N1 * Seronegative for H1N1 (with antibody titers ≤1:20) * Written informed consent to participate in this study Exclusion Criteria: * Acute febrile illness * Signs of acute or chronic upper or lower tract respiratory illnesses * History of severe atopy * Seasonal influenza vaccination from 2006/2007 onwards and/or pandemic influenza vaccination against H5N1 * Known increased tendency of nose bleeding * Volunteers with clinically relevant abnormal paranasal anatomy * Volunteers with clinically relevant abnormal laboratory values * Simultaneous treatment with immunosuppressive drugs * Clinically relevant history of renal, hepatic, GI, cardiovascular,haematological, skin, endocrine, neurological or immunological diseases * History of leukaemia or cancer * HIV or Hepatitis B or C seropositivity * Volunteers who underwent rhino or sinus surgery, or surgery of another traumatic injury of the nose within 30 days prior to application of study medication * Volunteers who have received antiviral drugs, treatment with immunoglobulins or blood transfusions, or an investigational drug within four weeks prior to study medication application * Volunteers who have received anti-inflammatory drugs 2 days prior to study medication application * Volunteers who are not likely to cope with the requirements of the study or with a significant physical or mental condition that may interfere with the completion of the study